New data from the Phase 2 OVATION 2 study highlights potential improvements in survival outcomes with IMUNON's IMNN-001 for ...

Cytokine therapies have the potential to transform cancer treatment by enhancing the body’s immune response to fight cancer ...

Comprehensive Genomic Profiling (CGP) is reshaping cancer treatment by enabling precision oncology at an unprecedented scale.

Promises of Innovation, Speed, and Savings,’ the latest research report by S&P Global Ratings. In a special session, we’ll ...

This novel DNA plasmid vaccine targets antigen-presenting cells and aims to induce a robust immune response. Prof. Lindy ...

Antibody-drug conjugates (ADCs) represent a significant breakthrough in oncology, offering targeted treatments, especially for lung cancer. In this insightful interview with Dr. Nicolas Girard, Head ...

The U.S. Food and Drug Administration (FDA) has approved Thermo Fisher’s Oncomine Dx Target Test, a next-generation sequencing (NGS)-based companion diagnostic, to identify patients eligible for ...

Researchers at Weill Cornell Medicine have made a breakthrough in the fight against hepatocellular carcinoma (HCC), by identifying a biomarker that could predict which patients are more likely to ...

The use of engineered viruses in cancer treatment is gaining significant traction, offering new avenues for enhancing immune responses against tumors. We had an insightful interview with Aino Kalervo, ...

Developed by AI, Lantern Pharma's investigational drug LP-184 has received FDA Fast-Track Designation for glioblastoma (GBM). LP-184, optimized using Lantern's AI platform RADR®, bypasses GBM’s ...